Qualigen Therapeutics (QLGN) Stock Price, News & Analysis

Company Overview

Qualigen Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a patent-protected rapid, onsite immunoassay testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, an oligonucleotide-based drug candidate to treat various nucleolin-expressing cancers, including liquid and solid tumors; QN-165, a drug candidate for the potential broad-spectrum treatment of infectious diseases, such as COVID-19; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and selective target antigen removal system, a therapeutic device to remove circulating tumor cells, viruses, inflammation factors, and immune checkpoints. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.

Key Stats

• Today's Range: $3.13 to $3.78
• 50-Day Range: $3.01 to $4.34
• 52-Week Range: $2.96 to $29.44
• Volume: 31,405 shs
• Average Volume: 99,386 shs
• Market Capitalization: $2.78 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

QLGN Stock Analysis - Frequently Asked Questions

How have QLGN shares performed this year?

Qualigen Therapeutics' stock was trading at $4.21 at the beginning of the year. Since then, QLGN stock has decreased by 10.2% and is now trading at $3.78.
View the best growth stocks for 2025 here.

How were Qualigen Therapeutics' earnings last quarter?

Qualigen Therapeutics, Inc. (NASDAQ:QLGN) posted its quarterly earnings results on Tuesday, August, 15th. The company reported ($34.50) earnings per share for the quarter, missing the consensus estimate of ($26.00) by $8.50. The business earned $1.63 million during the quarter, compared to analysts' expectations of $1.60 million.

When did Qualigen Therapeutics' stock split?

Qualigen Therapeutics's stock reverse split before market open on Tuesday, November 5th 2024. The 1-50 reverse split was announced on Friday, November 1st 2024. The number of shares owned by shareholders was adjusted after the closing bell on Monday, November 4th 2024. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split.

Who are Qualigen Therapeutics' major shareholders?

Top institutional investors of Qualigen Therapeutics include Concourse Financial Group Securities Inc.. Insiders that own company stock include Michael S Poirier and Amy S Broidrick.
View institutional ownership trends.

How do I buy shares of Qualigen Therapeutics?

Shares of QLGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Qualigen Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Qualigen Therapeutics investors own include Predictive Oncology (POAI), Ford Motor (F), Zomedica (ZOM), Bank of America (BAC), Wells Fargo & Company (WFC), JPMorgan Chase & Co. (JPM) and Abbott Laboratories (ABT).

Company Calendar

• Last Earnings: 8/15/2023
• Today: 3/27/2025
• Next Earnings (Estimated): 4/03/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:QLGN
• CIK: 1460702
• Web: www.qualigeninc.com
• Phone: (760) 918-9165
• Fax: N/A
• Employees: 50
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-13,420,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -424.18%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.52
• Quick Ratio: 0.52

Sales & Book Value

• Annual Sales: $4.98 million
• Price / Sales: 0.47
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($20.31) per share
• Price / Book: -0.16

Miscellaneous

• Outstanding Shares: 736,000
• Free Float: 723,000
• Market Cap: $2.36 million
• Optionable: Not Optionable
• Beta: 0.75